NYSEAMERICAN:SYN - Synthetic Biologics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.26 +0.01 (+4.00 %)
(As of 05/23/2018 01:24 AM ET)
Previous Close$0.25
Today's Range$0.25 - $0.27
52-Week Range$0.19 - $1.05
Volume697,800 shs
Average Volume798,841 shs
Market Capitalization$49.23 million
P/E RatioN/A
Dividend YieldN/A
Beta1.3

About Synthetic Biologics (NYSEAMERICAN:SYN)

Synthetic Biologics logoSynthetic Biologics, Inc., a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients. Its lead product candidates are in Phase III development, such as SYN-004 that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection, overgrowth of pathogenic organisms, and the emergence of antimicrobial resistance; and SYN-010 which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The company's preclinical products include an oral formulation of the enzyme intestinal alkaline phosphatase to treat local GI disorders and systemic diseases; monoclonal antibody therapies for the prevention and treatment of pertussis; and novel discovery stage biotherapeutics for the treatment of phenylketonuria. Synthetic Biologics, Inc. has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center. The company was formerly known as Adeona Pharmaceuticals, Inc. and changed its name to Synthetic Biologics, Inc. in February 2012. Synthetic Biologics, Inc. was founded in 2001 and is headquartered in Rockville, Maryland.

Receive SYN News and Ratings via Email

Sign-up to receive the latest news and ratings for SYN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:SYN
CUSIPN/A
Phone+1-734-3327800

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on Assets53.56%

Miscellaneous

EmployeesN/A
Outstanding Shares128,570,000

Synthetic Biologics (NYSEAMERICAN:SYN) Frequently Asked Questions

What is Synthetic Biologics' stock symbol?

Synthetic Biologics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "SYN."

How were Synthetic Biologics' earnings last quarter?

Synthetic Biologics Inc (NYSEAMERICAN:SYN) released its earnings results on Tuesday, May, 8th. The company reported ($0.02) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.03. View Synthetic Biologics' Earnings History.

What price target have analysts set for SYN?

2 equities research analysts have issued twelve-month price objectives for Synthetic Biologics' stock. Their predictions range from $10,000,000.00 to $0.00. On average, they expect Synthetic Biologics' share price to reach $0.00 in the next year. View Analyst Ratings for Synthetic Biologics.

Are investors shorting Synthetic Biologics?

Synthetic Biologics saw a decline in short interest in April. As of April 30th, there was short interest totalling 3,986,915 shares, a decline of 4.5% from the April 13th total of 4,176,771 shares. Based on an average daily trading volume, of 962,639 shares, the days-to-cover ratio is presently 4.1 days. Approximately 3.5% of the company's shares are sold short.

Who are some of Synthetic Biologics' key competitors?

Who are Synthetic Biologics' key executives?

Synthetic Biologics' management team includes the folowing people:
  • Mr. Steven A. Shallcross, Interim CEO, CFO, Sec., Treasurer & Sec. (Age 57)
  • Dr. Joseph A. Sliman, Chief Medical Officer (Age 45)
  • Vincent I. Perrone, Director of Corp. Communication
  • Dr. Michael Kaleko M.D., Ph.D., Sr. VP of R&D
  • Dr. Raymond D. Stapleton Jr., Ph.D., Sr. VP of Manufacturing

Has Synthetic Biologics been receiving favorable news coverage?

Media headlines about SYN stock have been trending somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Synthetic Biologics earned a news sentiment score of 0.18 on Accern's scale. They also gave media headlines about the company an impact score of 45.53 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Who are Synthetic Biologics' major shareholders?

Synthetic Biologics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Blair William & Co. IL (1.54%) and Millennium Management LLC (0.37%). View Institutional Ownership Trends for Synthetic Biologics.

Which institutional investors are selling Synthetic Biologics stock?

SYN stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC. View Insider Buying and Selling for Synthetic Biologics.

Which institutional investors are buying Synthetic Biologics stock?

SYN stock was purchased by a variety of institutional investors in the last quarter, including Blair William & Co. IL. View Insider Buying and Selling for Synthetic Biologics.

How do I buy shares of Synthetic Biologics?

Shares of SYN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Synthetic Biologics' stock price today?

One share of SYN stock can currently be purchased for approximately $0.26.

How big of a company is Synthetic Biologics?

Synthetic Biologics has a market capitalization of $49.23 million.

How can I contact Synthetic Biologics?

Synthetic Biologics' mailing address is 617 Detroit St Ste 100, ANN ARBOR, MI 48104-1125, United States. The company can be reached via phone at +1-734-3327800.


MarketBeat Community Rating for Synthetic Biologics (SYN)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  238 (Vote Outperform)
Underperform Votes:  135 (Vote Underperform)
Total Votes:  373
MarketBeat's community ratings are surveys of what our community members think about Synthetic Biologics and other stocks. Vote "Outperform" if you believe SYN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SYN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Synthetic Biologics (NYSEAMERICAN:SYN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Synthetic Biologics in the last 12 months. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.503.003.002.50
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/A$5.00$5.00$5.50
Price Target Upside: N/A863.39% upside863.39% upside959.73% upside

Synthetic Biologics (NYSEAMERICAN:SYN) Consensus Price Target History

Price Target History for Synthetic Biologics (NYSEAMERICAN:SYN)

Synthetic Biologics (NYSEAMERICAN:SYN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
5/18/2018HC WainwrightReiterated RatingBuyView Rating Details
5/9/2018Griffin SecuritiesDowngradeBuy ➝ HoldView Rating Details
5/22/2017William BlairReiterated RatingOutperform$5.00View Rating Details
1/14/2017FBR & CoReiterated RatingOverweight$6.00View Rating Details
11/25/2016LaurentianDowngradeBuy ➝ Speculative BuyView Rating Details
11/25/2016Laurentian Bank of CanadaDowngradeBuy ➝ Speculative BuyView Rating Details
8/25/2016BTIG ResearchInitiated CoverageBuy$5.00View Rating Details
(Data available from 5/23/2016 forward)

Earnings

Synthetic Biologics (NYSEAMERICAN:SYN) Earnings History and Estimates Chart

Earnings by Quarter for Synthetic Biologics (NYSEAMERICAN:SYN)

Synthetic Biologics (NYSEAMERICAN:SYN) Earnings Estimates

2018 EPS Consensus Estimate: ($0.14)
2019 EPS Consensus Estimate: $0.13
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.02)($0.02)($0.02)
Q2 20182($0.04)($0.04)($0.04)
Q3 20182($0.04)($0.04)($0.04)
Q4 20182($0.04)($0.04)($0.04)
Q1 20191($0.04)($0.04)($0.04)
Q2 20191($0.04)($0.04)($0.04)
Q3 20191($0.04)($0.04)($0.04)
Q4 20191$0.25$0.25$0.25

Synthetic Biologics (NYSEAMERICAN SYN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018Q1 2018($0.05)($0.02)ViewN/AView Earnings Details
2/22/2018Q4 2017($0.05)$0.02ViewN/AView Earnings Details
11/1/2017Q3 2017($0.0430)($0.14)ViewN/AView Earnings Details
8/3/2017Q2 2017($0.0570)($0.03)ViewListenView Earnings Details
5/4/2017Q1 2017($0.07)($0.02)ViewListenView Earnings Details
3/2/2017Q4 2016($0.08)($0.02)ViewListenView Earnings Details
11/1/2016Q316($0.10)($0.09)ViewN/AView Earnings Details
8/3/2016Q2 2016($0.12)($0.10)ViewN/AView Earnings Details
5/5/2016Q116($0.13)($0.12)ViewN/AView Earnings Details
3/10/2016Q415($0.12)($0.12)ViewListenView Earnings Details
11/5/2015Q315($0.12)($0.12)ViewN/AView Earnings Details
8/10/2015Q215($0.11)($0.19)ViewListenView Earnings Details
5/11/2015Q115($0.08)($0.11)ViewListenView Earnings Details
3/16/2015($0.06)($0.09)ViewN/AView Earnings Details
11/14/2014Q314($0.05)($0.08)ViewN/AView Earnings Details
8/14/2014($0.06)($0.08)ViewN/AView Earnings Details
5/15/2014Q1 14($0.08)($0.07)ViewN/AView Earnings Details
3/31/2014($0.06)($0.09)ViewN/AView Earnings Details
11/14/2013Q3($0.06)($0.08)ViewListenView Earnings Details
8/14/2013Q2 2013($0.06)($0.06)ViewN/AView Earnings Details
5/15/2013Q1 2013($0.05)($0.05)ViewN/AView Earnings Details
11/14/2012Q3 2012($0.05)ViewN/AView Earnings Details
8/14/2012Q2 2012($0.05)ViewN/AView Earnings Details
5/15/2012Q1 2012($0.06)ViewN/AView Earnings Details
11/14/2011Q3 2011($0.04)ViewN/AView Earnings Details
8/15/2011Q2 2011($0.06)ViewN/AView Earnings Details
5/16/2011Q1 2011($0.09)ViewN/AView Earnings Details
3/31/2011Q4 2010($0.04)ViewN/AView Earnings Details
11/15/2010Q3 2010($0.03)ViewN/AView Earnings Details
8/16/2010Q2 2010$0.04ViewN/AView Earnings Details
5/17/2010Q1 2010($0.05)ViewN/AView Earnings Details
11/16/2009Q3 2009($0.03)ViewN/AView Earnings Details
5/15/2009Q1 2009($0.01)ViewN/AView Earnings Details
4/1/2009Q4 2008($0.07)($0.04)ViewN/AView Earnings Details
8/14/2008Q2 2008($0.11)($0.09)ViewN/AView Earnings Details
5/15/2008Q1 2008($0.12)($0.15)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Synthetic Biologics (NYSEAMERICAN:SYN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Synthetic Biologics (NYSEAMERICAN SYN) Insider Trading and Institutional Ownership History

Insider Trading History for Synthetic Biologics (NYSEAMERICAN:SYN)
Institutional Ownership by Quarter for Synthetic Biologics (NYSEAMERICAN:SYN)

Synthetic Biologics (NYSEAMERICAN SYN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/17/2015Brendan CannonDirectorBuy5,000$0.3850$1,925.00
11/30/2015Christoper MartinDirectorBuy80,000$0.40$32,000.00
11/27/2015Bartley Vaden HeathDirectorBuy35,000$0.28$9,800.00
9/2/2015Randal J KirkMajor ShareholderBuy937,500$3.20$3,000,000.00View SEC Filing  
5/22/2014Charles Evan BallantyneCFOBuy10,000$1.35$13,500.00View SEC Filing  
4/29/2014Steve H KanzerDirectorSell263,112$2.90$763,024.80View SEC Filing  
12/17/2013Randal J KirkMajor ShareholderBuy2,500,000$1.00$2,500,000.00View SEC Filing  
1/7/2013Jeffrey Scott RileyCEOBuy2,900$0.17$493.00View SEC Filing  
1/3/2013Jeffrey Scott RileyCEOBuy2,000$1.71$3,420.00View SEC Filing  
10/29/2012Randal J KirkMajor ShareholderBuy3,125,000$1.60$5,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Synthetic Biologics (NYSEAMERICAN SYN) News Headlines

Source:
DateHeadline
Synthetic Biologics Announces Acceptance of Compliance Plan by NYSE AmericanSynthetic Biologics Announces Acceptance of Compliance Plan by NYSE American
finance.yahoo.com - May 22 at 8:45 AM
Synthetic Biologics (SYN) Now Covered by HC WainwrightSynthetic Biologics (SYN) Now Covered by HC Wainwright
www.americanbankingnews.com - May 18 at 3:08 PM
Synthetic Biologics, Inc. (SYN) Receives Consensus Rating of "Hold" from BrokeragesSynthetic Biologics, Inc. (SYN) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - May 18 at 11:47 AM
Synthetic Biologics, Inc. Forecasted to Post Q2 2018 Earnings of ($0.04) Per Share (SYN)Synthetic Biologics, Inc. Forecasted to Post Q2 2018 Earnings of ($0.04) Per Share (SYN)
www.americanbankingnews.com - May 14 at 1:38 AM
Synthetic Biologics (SYN) Raised to "Buy" at Zacks Investment ResearchSynthetic Biologics (SYN) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - May 12 at 6:05 PM
William Blair Analysts Raise Earnings Estimates for Synthetic Biologics, Inc. (SYN)William Blair Analysts Raise Earnings Estimates for Synthetic Biologics, Inc. (SYN)
www.americanbankingnews.com - May 11 at 8:15 AM
William Blair Equities Analysts Increase Earnings Estimates for Synthetic Biologics, Inc. (SYN)William Blair Equities Analysts Increase Earnings Estimates for Synthetic Biologics, Inc. (SYN)
www.americanbankingnews.com - May 10 at 9:07 AM
Synthetic Biologics, Inc. (SYN) Short Interest UpdateSynthetic Biologics, Inc. (SYN) Short Interest Update
www.americanbankingnews.com - May 10 at 1:20 AM
Synthetic Biologics (SYN) Stock Rating Lowered by Griffin SecuritiesSynthetic Biologics (SYN) Stock Rating Lowered by Griffin Securities
www.americanbankingnews.com - May 9 at 9:42 PM
Synthetic Biologics (SYN) Posts  Earnings Results, Beats Estimates By $0.03 EPSSynthetic Biologics (SYN) Posts Earnings Results, Beats Estimates By $0.03 EPS
www.americanbankingnews.com - May 9 at 12:59 PM
Selecta Biosciences Announces First Quarter 2018 Financial Results and Provides Corporate UpdateSelecta Biosciences Announces First Quarter 2018 Financial Results and Provides Corporate Update
globenewswire.com - May 9 at 9:06 AM
Synthetic Biologics (SYN) Management on Q1 2018 Results - Earnings Call TranscriptSynthetic Biologics' (SYN) Management on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 9:06 AM
Synthetic Biologics: 1Q Earnings SnapshotSynthetic Biologics: 1Q Earnings Snapshot
finance.yahoo.com - May 9 at 9:06 AM
Synthetic Biologics Reports First Quarter 2018 Operational Highlights and Financial ResultsSynthetic Biologics Reports First Quarter 2018 Operational Highlights and Financial Results
finance.yahoo.com - May 8 at 4:52 PM
Synthetic Biologics (SYN) Scheduled to Post Earnings on TuesdaySynthetic Biologics (SYN) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - May 2 at 9:42 PM
Global Oral Proteins and Peptides Market, 2018-2030 - Characterized by a Promising Development Pipeline, Featuring ...Global Oral Proteins and Peptides Market, 2018-2030 - Characterized by a Promising Development Pipeline, Featuring ...
www.prnewswire.com - May 2 at 4:52 PM
Synthetic Biologics, Inc. (SYN) Forecasted to Post FY2019 Earnings of $0.02 Per ShareSynthetic Biologics, Inc. (SYN) Forecasted to Post FY2019 Earnings of $0.02 Per Share
www.americanbankingnews.com - April 26 at 11:05 AM
Synthetic Biologics to Report First Quarter 2018 Operational Highlights and Financial Results on May 8, 2018Synthetic Biologics to Report First Quarter 2018 Operational Highlights and Financial Results on May 8, 2018
finance.yahoo.com - April 26 at 9:01 AM
Synthetic Biologics (SYN) Downgraded to Hold at Zacks Investment ResearchSynthetic Biologics (SYN) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - April 25 at 12:14 PM
Synthetic Biologics, Inc. Forecasted to Earn Q1 2019 Earnings of ($0.07) Per Share (SYN)Synthetic Biologics, Inc. Forecasted to Earn Q1 2019 Earnings of ($0.07) Per Share (SYN)
www.americanbankingnews.com - April 25 at 9:50 AM
Synthetic Biologics, Inc. (SYN) Short Interest Down 10.3% in AprilSynthetic Biologics, Inc. (SYN) Short Interest Down 10.3% in April
www.americanbankingnews.com - April 25 at 2:04 AM
Synthetic Bios SYN-004 loses accelerated review status for preventing C. diff infection; shares down 8% premarketSynthetic Bio's SYN-004 loses accelerated review status for preventing C. diff infection; shares down 8% premarket
seekingalpha.com - April 23 at 4:43 PM
BRIEF-Synthetic Biologics Provides Update On Development Of Syn-004 (RibaxamaseBRIEF-Synthetic Biologics Provides Update On Development Of Syn-004 (Ribaxamase
www.reuters.com - April 23 at 9:28 AM
Synthetic Biologics Provides Update on Development of SYN-004 (ribaxamase), for the Prevention of C. difficile InfectionSynthetic Biologics Provides Update on Development of SYN-004 (ribaxamase), for the Prevention of C. difficile Infection
finance.yahoo.com - April 23 at 9:28 AM
Global Synthetic Biology Market: Widening Application Base to Boost Market’s Growth, Says TMRGlobal Synthetic Biology Market: Widening Application Base to Boost Market’s Growth, Says TMR
globenewswire.com - April 19 at 9:21 AM
Synthetic Biologics (SYN) Stock Rating Upgraded by Zacks Investment ResearchSynthetic Biologics (SYN) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 12 at 11:29 AM
Synthetic Biologics, Inc. (SYN) Sees Significant Increase in Short InterestSynthetic Biologics, Inc. (SYN) Sees Significant Increase in Short Interest
www.americanbankingnews.com - April 10 at 6:58 PM
SGI-DNA Launches Automated Gene Libraries for Accelerated Drug Discovery and Development ResearchSGI-DNA Launches Automated Gene Libraries for Accelerated Drug Discovery and Development Research
www.bizjournals.com - March 29 at 9:19 AM
Synthetic Biologics (SYN) Downgraded by Zacks Investment Research to SellSynthetic Biologics (SYN) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - March 28 at 7:04 PM
Short Interest in Synthetic Biologics Inc (SYN) Drops By 9.1%Short Interest in Synthetic Biologics Inc (SYN) Drops By 9.1%
www.americanbankingnews.com - March 27 at 1:54 AM
Pre-Market Technical Scan on Biotech Equities -- Sorrento Therapeutics, Spark Therapeutics, Synthetic Biologics, and TG TherapeuticsPre-Market Technical Scan on Biotech Equities -- Sorrento Therapeutics, Spark Therapeutics, Synthetic Biologics, and TG Therapeutics
www.prnewswire.com - March 15 at 10:10 AM
Synthetic Biologics (SYN) Upgraded by Zacks Investment Research to "Buy"Synthetic Biologics (SYN) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - March 14 at 10:53 AM
Synthetic Biologics (SYN) Downgraded to "Hold" at Zacks Investment ResearchSynthetic Biologics (SYN) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 13 at 3:58 PM
Short Interest in Synthetic Biologics Inc (SYN) Expands By 0.7%Short Interest in Synthetic Biologics Inc (SYN) Expands By 0.7%
www.americanbankingnews.com - March 9 at 6:02 PM
Synthetic Biologics Reports on NYSE American Noncompliance Notice and Compliance Plan - PR Newswire (press release)Synthetic Biologics Reports on NYSE American Noncompliance Notice and Compliance Plan - PR Newswire (press release)
www.prnewswire.com - March 7 at 4:52 PM
Synthetic Biologics Reports on NYSE American Noncompliance Notice and Compliance PlanSynthetic Biologics Reports on NYSE American Noncompliance Notice and Compliance Plan
finance.yahoo.com - March 7 at 4:52 PM
Synthetic Biologics Inc (SYN) Short Interest Up 15.3% in FebruarySynthetic Biologics Inc (SYN) Short Interest Up 15.3% in February
www.americanbankingnews.com - February 27 at 5:40 PM
William Blair Comments on Synthetic Biologics Incs Q1 2018 Earnings (SYN)William Blair Comments on Synthetic Biologics Inc's Q1 2018 Earnings (SYN)
www.americanbankingnews.com - February 26 at 1:46 AM
Synthetic Biologics (SYN) Upgraded by Zacks Investment Research to "Hold"Synthetic Biologics (SYN) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - February 24 at 4:26 PM
Synthetic Biologics (SYN) Announces Quarterly  Earnings Results, Beats Estimates By $0.07 EPSSynthetic Biologics (SYN) Announces Quarterly Earnings Results, Beats Estimates By $0.07 EPS
www.americanbankingnews.com - February 23 at 5:18 PM
Synthetic Biologics Reports 2017 Year End Operational Highlights and Financial ResultsSynthetic Biologics Reports 2017 Year End Operational Highlights and Financial Results
finance.yahoo.com - February 22 at 9:00 AM
Synthetic Biologics to Report 2017 Year End Operational Highlights and Financial Results on February 22, 2018Synthetic Biologics to Report 2017 Year End Operational Highlights and Financial Results on February 22, 2018
finance.yahoo.com - February 15 at 4:55 PM
Synthetic Biologics Inc (SYN) Sees Large Decline in Short InterestSynthetic Biologics Inc (SYN) Sees Large Decline in Short Interest
www.americanbankingnews.com - February 9 at 6:36 PM
Stock Review for Biotechs Investors -- Spark Therapeutics, Synthetic Biologics, TG Therapeutics, and Zosano Pharma - PR Newswire (press release)Stock Review for Biotech's Investors -- Spark Therapeutics, Synthetic Biologics, TG Therapeutics, and Zosano Pharma - PR Newswire (press release)
www.prnewswire.com - February 6 at 3:25 PM
Synthetic Biologics Inc (SYN) Sees Significant Decrease in Short InterestSynthetic Biologics Inc (SYN) Sees Significant Decrease in Short Interest
www.americanbankingnews.com - January 25 at 1:32 AM
Synthetic Biologics Inc (SYN) Short Interest UpdateSynthetic Biologics Inc (SYN) Short Interest Update
www.americanbankingnews.com - January 11 at 1:22 AM
Synthetic Biologics to Present at the Biotech Showcase™ 2018 Conference - PR Newswire (press release)Synthetic Biologics to Present at the Biotech Showcase™ 2018 Conference - PR Newswire (press release)
www.prnewswire.com - January 2 at 9:33 PM
Synthetic Biologics to Present at the Biotech Showcase™ 2018 ConferenceSynthetic Biologics to Present at the Biotech Showcase™ 2018 Conference
finance.yahoo.com - January 2 at 4:33 PM
Synthetic Biologics Inc (SYN) Short Interest Down 13.1% in DecemberSynthetic Biologics Inc (SYN) Short Interest Down 13.1% in December
www.americanbankingnews.com - December 28 at 2:09 AM
Synthetic Biologics, Inc. (SYN) Short Interest Down 10.2% in NovemberSynthetic Biologics, Inc. (SYN) Short Interest Down 10.2% in November
www.americanbankingnews.com - December 12 at 1:50 AM

SEC Filings

Synthetic Biologics (NYSEAMERICAN:SYN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Synthetic Biologics (NYSEAMERICAN:SYN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Synthetic Biologics (NYSEAMERICAN SYN) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.